Talkspace vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Talkspace is an online therapy platform connecting users with licensed therapists via text, audio, and video, with coverage through major health plans and employers.
About
Talkspace is an online mental health company founded in 2012 that has become one of the most widely known telehealth therapy platforms, serving millions of users through its network of licensed therapists. The platform allows users to connect with therapists via asynchronous text messaging, live video sessions, and audio calls, offering flexibility that traditional in-person therapy cannot match. Talkspace is publicly traded on Nasdaq and generates a significant portion of revenue through health insurance coverage, with contracts including UnitedHealthcare, Cigna, and Aetna making therapy accessible to insured members. The company also offers a Talkspace for Business product serving employers as a mental health employee benefit. Talkspace has faced the challenge of demonstrating clinical outcomes comparable to in-person therapy while operating at a lower cost per session, and has invested in outcomes research to build evidence for its asynchronous text therapy modality. The company serves a broad range of mental health needs including anxiety, depression, relationship issues, and trauma, and has expanded into psychiatry for medication management. Talkspace operates in a competitive market alongside BetterHelp and other teletherapy platforms.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.